An Investigational Study of ESK-001 in Participants With Normal Renal Function and Participants With Mild, Moderate, and Severe Impaired Renal Function

Description

This a phase 1, open label, single dose, parallel cohort study to determine the pharmacokinetics (PK) of study drug (ESK-001) in healthy volunteer participants, and participants with mild, moderate, and severe renal impairment.

Conditions

Renal Impairment

Talk to us

Study Overview

On this page

Study Details

Study overview

This a phase 1, open label, single dose, parallel cohort study to determine the pharmacokinetics (PK) of study drug (ESK-001) in healthy volunteer participants, and participants with mild, moderate, and severe renal impairment.

A Phase 1, Open-label, Single-dose Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics of a Single Oral Dose of ESK-001

An Investigational Study of ESK-001 in Participants With Normal Renal Function and Participants With Mild, Moderate, and Severe Impaired Renal Function

Condition
Renal Impairment
Intervention / Treatment

-

Contacts and Locations

Miami Lakes

Panax Clinical Research, Miami Lakes, Florida, United States, 33014

Miami Lakes

Floridian Clinical Research, Miami Lakes, Florida, United States, 33016

Miami

Advanced Pharma CR, Miami, Florida, United States, 33147

Orlando

Orlando Clinical Research Center, Orlando, Florida, United States, 32809

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

    Ages Eligible for Study

    18 Years to 75 Years

    Sexes Eligible for Study

    ALL

    Accepts Healthy Volunteers

    Yes

    Collaborators and Investigators

    Alumis Inc,

    Jorn Drappa, Medical Director, STUDY_DIRECTOR, Alumis Inc

    Study Record Dates

    2025-12